Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma

Hyun Young Woo, doyoung kim, Jeong Heo, Chang Won Kim, Suk Kim, Ki Tae Yoon, Won Lim, Young Mi Hong, Jong Yun Won, Sangheun Lee, KwangHyub Han, Mong Cho

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Aim: The aim of this study was to investigate the effect of yttrium-90 radioembolization on the outcome of Asian patients with early to advanced stage hepatocellular carcinoma (HCC). Methods: Sixty-two patients were screened and 50 patients (80.6%) were eligible. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), and overall survival was estimated using the Kaplan–Meier method. Results: The Barcelona Clinic Liver Cancer (BCLC) stage was A in 40% of patients, B in 24%, and C in 36%; 66% of patients had hepatitis B virus infections. According to RECIST criteria, partial responses occurred in 40% of patients, and stable disease was achieved in 46%. Tumor response was significantly associated with BCLC stage (P = 0.003). The median overall time to progression was 5.8 months (range, 0.9–46.1 months). Follow-up treatments after radioembolization were carried out in 31 patients due to remnant HCC (n = 18) or HCC progression (n = 13). The median overall survival was 40.9 months (95% confidence interval, 10.2–71.6 months). Treatment was tolerable except for one lung toxicity and two hepatic toxicities. Conclusion: Yttrium-90 radioembolization appears to be well tolerated and effective in Asian patients with BCLC stage A–C HCC. Follow-up treatments after radioembolization can be safely provided.

Original languageEnglish
Pages (from-to)387-397
Number of pages11
JournalHepatology Research
Volume47
Issue number5
DOIs
Publication statusPublished - 2017 Apr 1

Fingerprint

Yttrium
Hepatocellular Carcinoma
Liver Neoplasms
Survival
Virus Diseases
Hepatitis B virus
Therapeutics
Confidence Intervals
Lung
Liver

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Infectious Diseases

Cite this

Woo, Hyun Young ; kim, doyoung ; Heo, Jeong ; Kim, Chang Won ; Kim, Suk ; Yoon, Ki Tae ; Lim, Won ; Hong, Young Mi ; Won, Jong Yun ; Lee, Sangheun ; Han, KwangHyub ; Cho, Mong. / Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma. In: Hepatology Research. 2017 ; Vol. 47, No. 5. pp. 387-397.
@article{7b231ec023a043f79f4f280c1aba3ceb,
title = "Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma",
abstract = "Aim: The aim of this study was to investigate the effect of yttrium-90 radioembolization on the outcome of Asian patients with early to advanced stage hepatocellular carcinoma (HCC). Methods: Sixty-two patients were screened and 50 patients (80.6{\%}) were eligible. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), and overall survival was estimated using the Kaplan–Meier method. Results: The Barcelona Clinic Liver Cancer (BCLC) stage was A in 40{\%} of patients, B in 24{\%}, and C in 36{\%}; 66{\%} of patients had hepatitis B virus infections. According to RECIST criteria, partial responses occurred in 40{\%} of patients, and stable disease was achieved in 46{\%}. Tumor response was significantly associated with BCLC stage (P = 0.003). The median overall time to progression was 5.8 months (range, 0.9–46.1 months). Follow-up treatments after radioembolization were carried out in 31 patients due to remnant HCC (n = 18) or HCC progression (n = 13). The median overall survival was 40.9 months (95{\%} confidence interval, 10.2–71.6 months). Treatment was tolerable except for one lung toxicity and two hepatic toxicities. Conclusion: Yttrium-90 radioembolization appears to be well tolerated and effective in Asian patients with BCLC stage A–C HCC. Follow-up treatments after radioembolization can be safely provided.",
author = "Woo, {Hyun Young} and doyoung kim and Jeong Heo and Kim, {Chang Won} and Suk Kim and Yoon, {Ki Tae} and Won Lim and Hong, {Young Mi} and Won, {Jong Yun} and Sangheun Lee and KwangHyub Han and Mong Cho",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/hepr.12759",
language = "English",
volume = "47",
pages = "387--397",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "5",

}

Woo, HY, kim, D, Heo, J, Kim, CW, Kim, S, Yoon, KT, Lim, W, Hong, YM, Won, JY, Lee, S, Han, K & Cho, M 2017, 'Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma', Hepatology Research, vol. 47, no. 5, pp. 387-397. https://doi.org/10.1111/hepr.12759

Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma. / Woo, Hyun Young; kim, doyoung; Heo, Jeong; Kim, Chang Won; Kim, Suk; Yoon, Ki Tae; Lim, Won; Hong, Young Mi; Won, Jong Yun; Lee, Sangheun; Han, KwangHyub; Cho, Mong.

In: Hepatology Research, Vol. 47, No. 5, 01.04.2017, p. 387-397.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of yttrium-90 radioembolization on outcomes in Asian patients with early to advanced stage hepatocellular carcinoma

AU - Woo, Hyun Young

AU - kim, doyoung

AU - Heo, Jeong

AU - Kim, Chang Won

AU - Kim, Suk

AU - Yoon, Ki Tae

AU - Lim, Won

AU - Hong, Young Mi

AU - Won, Jong Yun

AU - Lee, Sangheun

AU - Han, KwangHyub

AU - Cho, Mong

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Aim: The aim of this study was to investigate the effect of yttrium-90 radioembolization on the outcome of Asian patients with early to advanced stage hepatocellular carcinoma (HCC). Methods: Sixty-two patients were screened and 50 patients (80.6%) were eligible. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), and overall survival was estimated using the Kaplan–Meier method. Results: The Barcelona Clinic Liver Cancer (BCLC) stage was A in 40% of patients, B in 24%, and C in 36%; 66% of patients had hepatitis B virus infections. According to RECIST criteria, partial responses occurred in 40% of patients, and stable disease was achieved in 46%. Tumor response was significantly associated with BCLC stage (P = 0.003). The median overall time to progression was 5.8 months (range, 0.9–46.1 months). Follow-up treatments after radioembolization were carried out in 31 patients due to remnant HCC (n = 18) or HCC progression (n = 13). The median overall survival was 40.9 months (95% confidence interval, 10.2–71.6 months). Treatment was tolerable except for one lung toxicity and two hepatic toxicities. Conclusion: Yttrium-90 radioembolization appears to be well tolerated and effective in Asian patients with BCLC stage A–C HCC. Follow-up treatments after radioembolization can be safely provided.

AB - Aim: The aim of this study was to investigate the effect of yttrium-90 radioembolization on the outcome of Asian patients with early to advanced stage hepatocellular carcinoma (HCC). Methods: Sixty-two patients were screened and 50 patients (80.6%) were eligible. Response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST), and overall survival was estimated using the Kaplan–Meier method. Results: The Barcelona Clinic Liver Cancer (BCLC) stage was A in 40% of patients, B in 24%, and C in 36%; 66% of patients had hepatitis B virus infections. According to RECIST criteria, partial responses occurred in 40% of patients, and stable disease was achieved in 46%. Tumor response was significantly associated with BCLC stage (P = 0.003). The median overall time to progression was 5.8 months (range, 0.9–46.1 months). Follow-up treatments after radioembolization were carried out in 31 patients due to remnant HCC (n = 18) or HCC progression (n = 13). The median overall survival was 40.9 months (95% confidence interval, 10.2–71.6 months). Treatment was tolerable except for one lung toxicity and two hepatic toxicities. Conclusion: Yttrium-90 radioembolization appears to be well tolerated and effective in Asian patients with BCLC stage A–C HCC. Follow-up treatments after radioembolization can be safely provided.

UR - http://www.scopus.com/inward/record.url?scp=84989220991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989220991&partnerID=8YFLogxK

U2 - 10.1111/hepr.12759

DO - 10.1111/hepr.12759

M3 - Article

VL - 47

SP - 387

EP - 397

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 5

ER -